Clinical trial response and dropout rates with olanzapine versus risperidone

Annals of Pharmacotherapy

Volumn 37, Issue 4, 2003, Pages 556-563

  Santarlasci, Benedetta ^a   Messori, Andrea ^a   Yahni, Corinne Zara ^b   Demers, Denyse ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b NONE

Author keywords

Clinical trial; Dropout; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037380890     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C291     Document Type: Article

References (41)

1. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: an analysis. BMJ 1995;310:1433-8.
2. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999;37:81-7.
3. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999;354:13-9.
4. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
5. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-85.
6. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000;15:245-55.
7. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group. Epilepsia 1999;40:1767-74.
8. Pol S, Couzigou P, Bourliere M, Abergel A, Combis JM, Larrey D, et al. Randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J Hepatol 1999;31:1-7.
9. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
10. Samuelian JC, Hackett DA. Randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 1998;12:273-8.
11. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283:1303-10.
12. Walker MC, Li LM, Sander JW. Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome. BMJ 1996;313:1184-5.
13. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313:1169-74.
14. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-15.
15. Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: analysis of randomised controlled trials. BMJ 2000;321:1103-6.
16. Messori A, Trippoli S, Vaiani M, Cattel F. Survival analysis of individual patient data and survival analysis of published (aggregate) data. Clin Drug Invest 2000;20:309-16.
17. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54.
18. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-92.
19. Trallori G, Messori A, Scuffi C, Bardazzi G, Silvano R, d'Albasio G, et al. Effectiveness of 5-aminosalicylic acid enemas for maintaining remission in patients with left-sided ulcerative colitis: a meta- and economic analysis. J Clin Gastroenterol 1995;20:257-9.
20. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, et al. Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn's disease: an analysis. Am J Gastroenterol 1994;89:692-8.
21. Bardelli F, Messori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid alpha interferon on ALT in patients with chronic hepatitis C or chronic non-A non-B hepatitis: an analysis. Clin Drug Invest 1995;9:239-54.
22. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A. Relationship between cathepsin-D content and disease-free dropout rate in node-negative breast cancer patients: an analysis. Br J Cancer 1997;76:661-6.
23. Messori A, Bosi A, Bacci S, Laszlo D, Trippoli S, Locatelli F, et al. Retrospective dropout rate analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Bone Marrow Transplant 1999;23:489-95.
24. Messori A, Trippoli S, Becagli P. Zaccara G. Cost-effectiveness of riluzole in amyotrophic lateral sclerosis. Pharmacoeconomics 1999;16:153-63.
25. Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001;84:303-7.
26. Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. BMJ 1985;290:17-23.
27. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999;46:365-73.
28. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
29. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-58.
30. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
31. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-60.
32. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler G. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-11.
33. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505.
34. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48:1571-7.
35. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
36. Malla AK, Norman RM, Scholten DJ, Zirul S, Kotteda V. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry 2001;62:179-84.
37. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The Risperidone-USA-79 Study Group. N Engl J Med 2002;346:16-22.
38. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. BMJ 2000;321:1371-6.
39. Adams C, Duggan L. Atypical antipsychotics in the treatment of schizophrenia. Paper corrupts concept of evidence based medicine. BMJ 2001;322:927-8.
40. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001;24:59-73.
41. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243.